Details for Patent: 11,896,562
Which drugs does patent 11,896,562 protect, and when does it expire?
Patent 11,896,562 protects EVEKEO ODT and is included in one NDA.
Summary for Patent: 11,896,562
| Title: | Oral amphetamine composition |
| Abstract: | In various embodiments, the present invention is directed to oral pharmaceutical compositions. For example, in some embodiments, the present invention is directed to taste-masked compositions. In some embodiments, the taste masked compositions comprise a highly water soluble drug such as amphetamine, e.g., in the form of a salt such as amphetamine sulfate. In various embodiments, the present invention is directed to taste-masked, orally disintegrating compositions. |
| Inventor(s): | Gopi Venkatesh, Michelle Schilling |
| Assignee: | Adare Pharma Solutions Inc |
| Application Number: | US17/493,949 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; |
Drugs Protected by US Patent 11,896,562
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azurity | EVEKEO ODT | amphetamine sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 209905-001 | Jan 30, 2019 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN PEDIATRIC PATIENTS | ⤷ Start Trial | ||||
| Azurity | EVEKEO ODT | amphetamine sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 209905-002 | Jan 30, 2019 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN PEDIATRIC PATIENTS | ⤷ Start Trial | ||||
| Azurity | EVEKEO ODT | amphetamine sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 209905-003 | Jan 30, 2019 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN PEDIATRIC PATIENTS | ⤷ Start Trial | ||||
| Azurity | EVEKEO ODT | amphetamine sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 209905-004 | Jan 30, 2019 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN PEDIATRIC PATIENTS | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
